{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:54:40Z","timestamp":1791507280158,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.14283\/jpad.2024.36","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:02:41Z","timestamp":1707091361000},"page":"549-557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies"],"prefix":"10.1016","volume":"11","author":[{"given":"N.D.","family":"Prins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Blackburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-M.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Galvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14283\/jpad.2024.36_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/13543784.2019.1681398","article-title":"Clinical drug development for dementia with Lewy bodies: past and present","volume":"28","author":"Lee","year":"2019","journal-title":"Exp. Opin Invest Drugs"},{"key":"10.14283\/jpad.2024.36_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gaitpost.2016.08.009","article-title":"Motor performance differentiates individuals with Lewy body dementia, Parkinson's and Alzheimer's disease","volume":"50","author":"Fritz","year":"2016","journal-title":"Gait & posture"},{"key":"10.14283\/jpad.2024.36_bib3","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.JGP.0000216177.08010.f4","article-title":"More severe functional impairment in dementia with lewy bodies than Alzheimer disease is related to extrapyramidal motor dysfunction","volume":"14","author":"McKeith","year":"2006","journal-title":"Am J of Geriatr Psychiatry"},{"key":"10.14283\/jpad.2024.36_bib4","doi-asserted-by":"crossref","first-page":"e010357","DOI":"10.1136\/bmjopen-2015-010357","article-title":"Cognitive decline in dementia with Lewy bodies: a 5-year prospective cohort study","volume":"6","author":"Rongve","year":"2016","journal-title":"BMJ Open"},{"key":"10.14283\/jpad.2024.36_bib5","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s13670-013-0053-6","article-title":"Update on Dementia with Lewy Bodies","volume":"2","author":"Karantzoulis","year":"2013","journal-title":"Curr Transl Geriatr Exp Gerontol Rep"},{"key":"10.14283\/jpad.2024.36_bib6","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S1474-4422(17)30074-1","article-title":"The prognosis of dementia with Lewy bodies","volume":"16","author":"Mueller","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.14283\/jpad.2024.36_bib7","first-page":"289","article-title":"Therapeutic trials and Dementia with Lewy bodies: a systematic review of the literature","volume":"19","author":"Sacrez","year":"2021","journal-title":"Geriatr Psychol Neuropsychiatr Vieil"},{"key":"10.14283\/jpad.2024.36_bib8","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1038\/s41467-022-32944-3","article-title":"Preclinical and randomized clinical evaluation of the p38alpha kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration","volume":"13","author":"Jiang","year":"2022","journal-title":"Nat Commun"},{"key":"10.14283\/jpad.2024.36_bib9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13024-023-00663-y","article-title":"Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come","volume":"18","author":"Alam","year":"2023","journal-title":"Mol Neurodegen"},{"key":"10.14283\/jpad.2024.36_bib10","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.3390\/ijms21155485","article-title":"P38 MAPK Signaling\u2014A Robust Therapeutic Target for Rab5-Mediated Neurodegenerative Disease","volume":"21","author":"Germann","year":"2020","journal-title":"Int. J. Mol. Sci"},{"key":"10.14283\/jpad.2024.36_bib11","doi-asserted-by":"crossref","first-page":"e1708","DOI":"10.1212\/WNL.0000000000207755","article-title":"Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies","volume":"101","author":"Alam","year":"2023","journal-title":"Neurology"},{"issue":"4","key":"10.14283\/jpad.2024.36_bib12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/acn3.549","article-title":"An exploratory clinical study of p38a kinase inhibition in Alzheimer's disease","volume":"5","author":"Scheltens","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"10.14283\/jpad.2024.36_bib13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"10.14283\/jpad.2024.36_bib14","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/nn.3101","article-title":"Large-scale cortical correlation structure of spontaneous oscillatory activity","volume":"15","author":"Hipp","year":"2012","journal-title":"Nat Neurosci"},{"issue":"8","key":"10.14283\/jpad.2024.36_bib15","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1093\/brain\/awac093","article-title":"Structural (dys)connectivity associates with cholinergic cell density in Alzheimer's disease","volume":"145","author":"Lin","year":"2022","journal-title":"Brain"},{"key":"10.14283\/jpad.2024.36_bib16","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/alz.12334","article-title":"Characterization of dementia with Lewy bodies (DLB) and mildcognitive impairment using the Lewy body dementia module(LBD-MOD)","volume":"17","author":"Galvin","year":"2021","journal-title":"Alzheimer's Dement"},{"issue":"17","key":"10.14283\/jpad.2024.36_bib17","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","article-title":"Research criteria for the diagnosis of prodromal dementia with Lewy bodies","volume":"94","author":"McKeith","year":"2020","journal-title":"Neurology"},{"key":"10.14283\/jpad.2024.36_bib18","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/mds.28370","article-title":"Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease","volume":"36","author":"Hall","year":"2021","journal-title":"Mov Disord"},{"key":"10.14283\/jpad.2024.36_bib19","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamaneurol.2020.4986","article-title":"Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease","volume":"78","author":"Moscoso","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.14283\/jpad.2024.36_bib20","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1093\/brain\/awac093","article-title":"Structural (dys)connectivity associates with cholinergic cell density in Alzheimer's disease","volume":"145","author":"Lin","year":"2022","journal-title":"Brain"},{"key":"10.14283\/jpad.2024.36_bib21","unstructured":"Lin C-P, Noteboom S, Alam J, et al. Effects of the p38\u03b1 kinase inhibitor neflamapimod on the basal forebrain in patients, assessed by structural MRI. Abstract at the 17th International Conference on Alzheimer's and Parkinson's Diseases, Gothenburg, Sweden, March 28\u2013April 1, 2023."},{"issue":"3","key":"10.14283\/jpad.2024.36_bib22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000048651","article-title":"Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system","volume":"13","author":"Wesnes","year":"2002","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.14283\/jpad.2024.36_bib23","doi-asserted-by":"crossref","first-page":"pyv086","DOI":"10.1093\/ijnp\/pyv086","article-title":"Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis","volume":"19","author":"Matsunaga","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"10.14283\/jpad.2024.36_bib24","doi-asserted-by":"crossref","first-page":"fcac013","DOI":"10.1093\/braincomms\/fcac013","article-title":"Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration","volume":"4","author":"Kantarci","year":"2022","journal-title":"Brain Commun"},{"key":"10.14283\/jpad.2024.36_bib25","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/mds.28453","article-title":"Cholinergic basal forebrain volumes predict gait decline in Parkinson's Disease","volume":"36","author":"Wilson","year":"2021","journal-title":"Mov. Disord"},{"key":"10.14283\/jpad.2024.36_bib26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40120-022-00417-w","article-title":"Disease Progression and Longitudinal Clinical Outcomes of Lewy Body Dementia in the NACC Database","volume":"12","author":"Chandler","year":"2023","journal-title":"Neurol Ther"},{"key":"10.14283\/jpad.2024.36_bib27","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1212\/WNL.0000000000003512","article-title":"Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB","volume":"88","author":"Thomas","year":"2017","journal-title":"Neurology"},{"key":"10.14283\/jpad.2024.36_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamaneurol.2021.4222","article-title":"Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies","volume":"79","author":"Gonzale","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.14283\/jpad.2024.36_bib29","first-page":"S13","article-title":"Results of a phase 2\/3 placebo-controlled, double-blind, parallel-group, randomized study to evaluate the efficacy and safety of 12-week treatment with the phosphodiesterase 9 (PDE9) inhibitor irsenontrine (E2027) in subjects with dementia with Lewy bodies","volume":"9","author":"Irizarry","year":"2022","journal-title":"J Prev Alz Dis"},{"key":"10.14283\/jpad.2024.36_bib30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nat Med"},{"key":"10.14283\/jpad.2024.36_bib31","doi-asserted-by":"crossref","first-page":"13249","DOI":"10.1038\/ncomms13249","article-title":"The-Alzheimer's-Disease-Neuroimaging-Initiative. Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology","volume":"7","author":"Schmitz","year":"2016","journal-title":"Nat Commun"},{"key":"10.14283\/jpad.2024.36_bib32","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/brain\/awaa012","article-title":"Basal forebrain volume reliably predicts the cortical spread of Alzheimer's degeneration","volume":"143","author":"Fernandez-Cabello","year":"2020","journal-title":"Brain"},{"key":"10.14283\/jpad.2024.36_bib33","doi-asserted-by":"crossref","first-page":"e947","DOI":"10.1212\/WNL.0000000000013277","article-title":"Association of beta-Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra","volume":"98","author":"Yoo","year":"2022","journal-title":"Neurology"},{"key":"10.14283\/jpad.2024.36_bib34","doi-asserted-by":"crossref","first-page":"e053979","DOI":"10.1002\/alz.053979","article-title":"Dementia with Lewy bodies (DLB) with amyloid co-pathology has a distinct CSF proteomics profile compared to pure DLB and Alzheimer disease","volume":"17","author":"Vermunt","year":"2021","journal-title":"Alzheimer's & Dementia"},{"issue":"6","key":"10.14283\/jpad.2024.36_bib35","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/hbm.24896","article-title":"Weighted network measures reveal differences between dementia types: An EEG study","volume":"41","author":"Mehraram","year":"2020","journal-title":"Hum Brain Mapp"},{"issue":"1","key":"10.14283\/jpad.2024.36_bib36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13195-020-00613-6","article-title":"EEG alpha reactivity and cholinergic system integrity in Lewy body dementia and Alzheimer's disease","volume":"12","author":"Schumacher","year":"2020","journal-title":"Alzheimers Res Ther"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724000475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724000475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T21:08:03Z","timestamp":1737320883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724000475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2274580724000475"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2024.36","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2024.36","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}